|
|
|
A standing-room only crowd at BIO enjoyed a candid discussion between BIO CEO Jim Greenwood and keynote speaker, Former Secretary of State (and potential 2016 Presidential contender) Hillary Clinton.
|
|
In addition to covering global issues, she reinforced her position that there is work to be done domestically to facilitate and encourage more US-based risk taking in the biotechnology field.
|
|
|
The Chief Biotech Officer of Johnson & Johnson, Jay Siegel, participated in the Tuesday Keynote Luncheon, representing Janssen's sponsorship of the BioGENEius Challenge Awards, which supports and honors young, highly talented scientists.
|
|
|
|
|
Johnson & Johnson announced the 2014 winners of the Dr. Paul Janssen Award with a ceremony led by Johnson & Johnson, VP of Innovation, Global Health & Policy Communications, Seema Kumar.
Watch remarks from winners Drs. Doudna & Charpentier on their work in genome engineering.
|
|
|
Peter Lebowitz, Global Therapeutic Area Head of Oncology, Janssen Research & Development, as featured during the BIO Super Session "Integrate and Collaborate to Drive Advancements in Oncology Treatments." Read the coverage of the session from Biotech Now.
|
|
|
Johnson & Johnson was host to more than 1,000 attendees at the Make the Connection Partner reception and the Asia Pacific Delegate reception. J&J Innovation Asia Pacific will officially launch later this year. Thank you for making the time to connect with us.
|
|
|
Johnson & Johnson added some "heat" to the BIO Gaslamp reception which included a Make the Connection themed flash mob.
|
|
Check out the full video here.
Check out the feature about the Flash Mob in BIO Buzz Reception Highlights.
|
|
|
Janssen Labs team members provided overviews and tours of the flagship, 40,000sf, 'no strings attached' incubator and by the conclusion of BIO was host to over 400 visitors from 16 different countries.
|
|
Missed the tour? Sign-up for an upcoming tour at one of our locations here.
|
|
|
Janssen Labs is part of Johnson & Johnson's external R&D engine and provides a capital-efficient, resource-rich environment where emerging companies can transform the scientific discoveries of today into the breakthrough healthcare products of tomorrow. The Janssen Labs network encompasses a 40,000 square foot flagship facility in San Diego at Janssen's West Coast Research Center, dedicated space within Lab Central in Boston and QB3@953 in San Francisco, as well as a 30,000 square foot stand-alone facility in South San Francisco (opening 2015). The facilities feature core research labs hosting specialized capital equipment, shared administrative areas and individual bench, wet lab and office modules on a short term basis. Companies pay only for the space they need, with an option to quickly expand when they have the resources to do so. An operations team allows our companies to focus on the science and our business team provides access to education, experts and funding partners. Janssen Labs is a no strings attached model and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen. Janssen Labs services and amenities vary depending on location. For more information, visit www.janssenlabs.com.
|
|
|
Johnson & Johnson Innovation, LLC focuses on accelerating early-stage innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local deal-making capabilities with the flexibility to adapt deal structures to match early-stage opportunities and establish novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit: www.jnjinnovation.com.
|
|
|
|
Meet the Team
|
Meet Melinda Richter, Head of Janssen Labs. Melinda, an investor in early stage biotech, is an extreme sport addict: she heli-boards in Alaska and dives with sharks.
Meet Diego Miralles, Global Head of Innovation, Janssen Pharmaceutical Companies of J&J. Diego - who had several career choices: medicine, nuclear physics or priesthood - chose medicine and has no regrets.
Meet Robert Urban, Head of J&J Boston Innovation Center. Robert was born ready. Contact him if you are!
Meet Ken Drazan, Head of J&J Innovation Center in California. Ken hitchhiked from Beijing to Lhasa.
Meet Peter Lebowitz, Global Oncology Therapeutic Area Head, for Janssen, Pharmaceutical Companies of J&J. In high school, Peter was in a band called the "Rotten Tomatoes" because someone threw a tomato at them at their first performance.
Meet Darren Snellgrove, Chief Financial Officer for the J&J Innovation Centers and JJDC. Contrary to popular belief, Darren's accent is not Australian, or South African...
To find out more about J&J or other team members email: jnjinnovation@its.jnj.com.
|
|
